To include your compound in the COVID-19 Resource Center, submit it here.

Peregrine reports Cotara data

Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) reported additional data from a Phase II trial in

Read the full 135 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE